Cerus Corporation will release its financial results for the second quarter of 2026 on July 30, 2026, following the close of the stock market. The company has scheduled a conference call and webcast at 4:30 P.M. ET on the same day to review the financial performance and provide a general business overview and outlook.

Management will discuss the quarterly results during the live event, which will be accessible via the Investor Relations page on the Cerus website. Participants can register for the call online, and while early registration is not mandatory, attendees are encouraged to join 10 minutes before the start time.

A replay of the conference call will be made available on the Cerus website approximately three hours after the event concludes. The replay will remain accessible until August 20, 2026, allowing stakeholders to listen at their convenience.

Cerus Corporation focuses on safeguarding the blood supply through its pathogen reduction technologies. The company’s INTERCEPT Blood System for platelets and plasma is available globally and holds both CE mark and FDA approval. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing a therapeutic product used to control bleeding associated with fibrinogen deficiency. The INTERCEPT red blood cell system is currently under regulatory review in Europe and in late-stage clinical development in the U.S.

Cerus has announced a significant restructuring of its executive leadership, effective July 1, 2026. William Greenman will step down from his positions as President and Chief Executive Officer to transition into the role of Executive Chairman. This strategic shift in leadership was detailed in a recent regulatory filing submitted to the Securities and Exchange Commission.

The transition marks a change in the company's executive hierarchy while retaining Greenman's expertise within the organization. By moving to the Executive Chairman role, Greenman will continue to provide oversight and strategic guidance to the board and management team. The filing confirms the specific date of July 1, 2026, for these changes to take effect.

The announcement provides the necessary details regarding the personnel changes but does not specify the immediate successor for the President and CEO roles in the provided document. The move ensures continuity at the board level while facilitating a change in the company's operational leadership structure.